Please replace the release with the following corrected version due to revisions in the Important Safety Information section and the addition of an embedded link to the “Prescribing Information.” Also, a PDF document has been included as an additional multimedia asset.
The Iclusig™ bottle (Photo: Business Wire)
The corrected release reads:
ARIAD ANNOUNCES ACCELERATED APPROVAL BY FDA OF ICLUSIG (PONATINIB) FOR PATIENTS WITH CML AND PH+ ALL RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY
Approved for All Phases of CML
Product Expected to be Available to Patients Within Approximately Two Weeks
Conference Call Scheduled Today at 1:30 p.m. ET
ARIAD Pharmaceuticals, Inc.
(NASDAQ: ARIA) today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig™ (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
“Today’s FDA approval of Iclusig is an important advance in the treatment of patients with CML and Ph+ ALL who are resistant or intolerant to prior TKI therapy,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “Within less than five years, we were able to bring Iclusig from the start of clinical development to U.S. approval, achieving a major milestone in ARIAD’s history. We have now transformed ARIAD into a commercial oncology company addressing major unmet medical needs for cancer patients.”
Approximately 5,000 new cases of CML are diagnosed each year in the U.S. CML patients treated with TKIs can develop resistance or intolerance over time to these therapies. Iclusig is a targeted cancer medicine discovered and developed at ARIAD. It was designed by ARIAD scientists using ARIAD’s platform of computational chemistry and structure-based drug design to inhibit BCR-ABL, including drug-resistant mutants that arise during treatment. Iclusig is the only TKI that demonstrates activity against the T315I gatekeeper mutation of BCR-ABL, the most common mutation occurring in approximately ten percent of patients with drug resistance.